- 4,000 men will be diagnosed with prostate cancer
this year - Structured approach to early
detection of prostate cancer could lead to a 40% reduction
in mortality
Prostate cancer is now New
Zealand’s most diagnosed cancer and one in eight men will
get prostate cancer in their lifetime. Yet, despite all
evidence pointing to early detection making the difference
between life and death, the third biggest killer of men in
this country is not prioritised in the same way as breast,
bowel and cervical cancer.
Hosted at Wellington’s Te
Papa Museum today, Sunday 28th August, Prostate Cancer
Foundation of New Zealand (PCFNZ) held its first conference
in two years with a range of senior voices and specialists
from Aotearoa New Zealand and overseas, discussing some of
the greatest challenges that face the country in terms of
the screening, diagnosis and treatment of prostate
cancer.
Conference keynote speaker from the European
Association of Urology, Professor Doctor Hendrik Van Poppel,
joined the conference via video link from Europe and
outlined how a structured approach to early detection of
prostate cancer could lead to a 40% reduction in mortality
in New Zealand.
Van Poppel, a world-leading expert in
early detection of the disease, presented to the conference
on how informed discussions between men and their GPs, the
use of a simple PSA* blood test and MRI scanning of men
subsequently discovered to be at risk would result in fewer
men undergoing unnecessary invasive investigations than do
currently, a sizeable drop in deaths from prostate cancer,
and better quality of life for those
diagnosed.
“Despite the fact we have access to
better diagnosis and treatment, recommendations against
organised screening have led to increased mortality rates
across many parts of Europe and America,” Van Poppel told
the conference. “In the UK, more men now die of prostate
cancer than women die of breast cancer, and it is Sweden’s
number one killer of men.
“Organised screening is
the solution needed to stop the increasing rate of too late
diagnosis, decrease prostate cancer deaths, stop costly and
ineffective opportunistic testing and importantly improve
the quality of life of prostate cancer
patients.”
Professor Doctor Hendrik Van Poppel, and
his colleagues, have made recommendations to the European
Union and the European Community, and he is hopeful that
European Union guidelines will be updated to include the
need for structured organised testing for prostate cancer as
early as December this year.
“Prostate cancer is the
most diagnosed cancer in New Zealand but if it’s caught
early, it is also treatable,” says the Foundation’s CEO,
Peter Dickens. “It’s extremely frustrating and should be
an issue of national concern in New Zealand that despite all
evidence pointing to early detection and appropriate
treatment making the difference between life and death,
methods of detecting the disease, treatments and medicines
for prostate cancer patients that are considered standard
and funded in other countries are severely limited here, or
even non-existent outside of the main
centres.
“Inequities are also painfully evident, as
the figures clearly show that tāne Māori diagnosed with
prostate cancer experience a disproportionally higher death
rate than other New Zealand men. It’s unnecessary and we
should all find it unacceptable.”
Also welcomed at
the conference was PCFNZ’s new president, Danny
Bedingfield, who was himself diagnosed with prostate cancer
at the young age of 37, just nine months after his father
lost his five year battle with advanced prostate cancer.
He’s a fierce advocate for younger men to get tested and
has been part of multiple media campaigns during Blue
September to try and raise awareness around the benefits of
regular PSA testing.
“Men are still reluctant to
talk about prostate cancer,’” says Danny. “And I am on
a mission to change that. We must encourage all men over 50
to have a conversation with their doctor about prostate
cancer, insist on a programme of PSA testing appropriate to
them and if they have a family history of prostate cancer,
they need to do it much earlier. I am living proof that
early detection can be the difference between life and
death, sadly my father didn’t have that
opportunity.
“The 42,000 men currently living with
prostate cancer in New Zealand are not just a statistic,
they are all dads, sons, grandads, and best mates who do not
deserve to have the opportunity to share in the lives of
their families and those around them taken away far too
soon.”
PCFNZ is committed to being the voice of men
living with the disease in New Zealand, advocating on their
behalf for better health outcomes today and for future
generations. Blue September is the charity’s primary
fundraising event, across the country Kiwis are encouraged
to support the 1 in 8 men and their whānau affected by
prostate cancer and Do Something Blue to help a mate through
during the month of September – www.blueseptember.org.nz.
*PSA
is a simple blood test use primarily to screen for prostate
cancer.
About PCFNZ
PCFNZ plays a vital role
in raising awareness of prostate cancer in Aotearoa New
Zealand. It has 45 support networks across New Zealand
providing valuable support and resources to men with
prostate cancer and their families. Every year PCFNZ commits
significant funds to New Zealand-based research on finding
better diagnosis and treatment options for prostate cancer.
The Foundation is 100% funded by donors and receives no
direct government funding.
PCFNZ is supporting
Kristine Hayward’s petition calling for an early prostate
detection strategy, to sign the petition click here.
Kristine’s husband died of prostate cancer, and she
believes, “testing is unfunded, disorganised, and
inequitable. Inequities in testing allow too many men to
die, with Māori and rural men disproportionately affected.
We need a structured, population-based testing approach for
early detection of prostate cancer in men over 50 (40 with a
family history), just as we have with breast
cancer.”
© Scoop Media



















Discussion about this post